Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Akebia Therapeutics, Inc is a biotechnology business based in the US. Akebia Therapeutics shares (AKBA) are listed on the NASDAQ and all prices are listed in US Dollars. Akebia Therapeutics employs 358 staff and has a trailing 12-month revenue of around USD$340.2 million.
Since the stock market crash in March caused by coronavirus, Akebia Therapeutics's share price has had significant negative movement.
Its last market close was USD$2.6, which is 74.38% down on its pre-crash value of USD$10.15 and 46.35% down on the lowest point reached during the March crash when the shares fell as low as USD$3.805.
If you had bought USD$1,000 worth of Akebia Therapeutics shares at the start of February 2020, those shares would have been worth USD$791.09 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$330.15.
|Latest market close||USD$2.6|
|52-week range||USD$2.34 - USD$13.71|
|50-day moving average||USD$3.4543|
|200-day moving average||USD$9.0134|
|Wall St. target price||USD$6.86|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.395|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-23)||-15.31%|
|1 month (2020-10-30)||17.12%|
|3 months (2020-08-28)||-74.71%|
|6 months (2020-05-29)||-77.66%|
|1 year (2019-11-29)||-58.66%|
|2 years (2018-11-30)||-67.82%|
|3 years (2017-11-30)||-83.29%|
|5 years (2015-11-30)||-75.77%|
|Revenue TTM||USD$340.2 million|
|Gross profit TTM||USD$26.5 million|
|Return on assets TTM||-14.83%|
|Return on equity TTM||-86.68%|
|Market capitalisation||USD$530.3 million|
TTM: trailing 12 months
There are currently 22.2 million Akebia Therapeutics shares held short by investors – that's known as Akebia Therapeutics's "short interest". This figure is 141.8% up from 9.2 million last month.
There are a few different ways that this level of interest in shorting Akebia Therapeutics shares can be evaluated.
Akebia Therapeutics's "short interest ratio" (SIR) is the quantity of Akebia Therapeutics shares currently shorted divided by the average quantity of Akebia Therapeutics shares traded daily (recently around 12.0 million). Akebia Therapeutics's SIR currently stands at 1.85. In other words for every 100,000 Akebia Therapeutics shares traded daily on the market, roughly 1850 shares are currently held short.
However Akebia Therapeutics's short interest can also be evaluated against the total number of Akebia Therapeutics shares, or, against the total number of tradable Akebia Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Akebia Therapeutics's short interest could be expressed as 0.15% of the outstanding shares (for every 100,000 Akebia Therapeutics shares in existence, roughly 150 shares are currently held short) or 0.1781% of the tradable shares (for every 100,000 tradable Akebia Therapeutics shares, roughly 178 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Akebia Therapeutics.
Find out more about how you can short Akebia Therapeutics stock.
We're not expecting Akebia Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Akebia Therapeutics's shares have ranged in value from as little as $2.34 up to $13.71. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Akebia Therapeutics's is 1.6459. This would suggest that Akebia Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. It has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds worldwide. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.